Rakovina Therapeutics reported a net loss of $1,781,757 CAD for Q3 2025, with R&D expenses of $1,102,371 CAD and G&A expenses of $539,174 CAD1
Cash and cash equivalents as of September 30, 2025 were $822,293 CAD, down from $1,312,743 CAD at the end of 20241
The company presented pre-clinical data on October 27, 2025 at the AACR-NCI-EORTC International Conference showing its AI-discovered ATR inhibitor program (kt-5000 series) achieved potent ATR inhibition with confirmed CNS penetration1
On January 27, 2026, Rakovina announced a proposed $1.0 million convertible debenture and concurrent $500,000 private placement to support near-term operations6
The company reached an agreement in principle with one debenture holder to convert $1.0 million of outstanding principal plus $50,000 in accrued interest into replacement debentures6
Rakovina's common shares became eligible for electronic clearing and settlement through the Depository Trust Company (DTC) on July 15, 20251
The company has established a pipeline of DNA-damage response inhibitors with the goal of advancing drug candidates into human clinical trials in collaboration with pharmaceutical partners1
Sources:
1. https://www.rakovinatherapeutics.com/rakovina-therapeutics-announces-three-month-q3-ended-september-30-2025-financial-results-and-provides-corporate-update/
6. https://markets.businessinsider.com/news/stocks/rakovina-therapeutics-announces-corporate-update-including-up-to-1-5-million-in-new-financing-leadership-appointments-and-debt-restructuring-1035752135